Mersana Therapeutics provides business update, expected milestones

Mersana Therapeutics provided a business update and announced strategic objectives and expected milestones for 2023. "Following a year of tremendous accomplishment in 2022, we are now approaching top-line data from our first registrational trial of UpRi, which we believe will provide an opportunity to further demonstrate Mersana’s increasing role as an ADC leader," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "The data we expect to report from our UPLIFT clinical trial in mid-2023 will represent the most significant milestone to date in our effort to establish UpRi as a foundational medicine for patients with ovarian cancer. Assuming positive data, we plan to target the submission of a BLA around the end of 2023 and prepare for a potential U.S. commercial launch in 2024. We will also continue to advance our UP-NEXT and UPGRADE-A trials of UpRi in earlier lines of treatment." Strategic Objective: Establish UpRi as a Foundational Medicine in Ovarian Cancer – Expected Milestones: Report top-line data from UPLIFT in mid-2023; Assuming positive data, submit a biologics license application to the U.S. Food and Drug Administration around the end of 2023; Prepare for potential U.S. accelerated approval and commercial launch in 2024; Significantly advance enrollment of UP-NEXT in 2023; and Initiate dose expansion portion of UPGRADE-A in the first quarter of 2023 and report interim data from UPGRADE-A in the second half of 2023. Strategic Objective: Advance Clinical-Stage Pipeline – expected Milestones: XMT-1660: Complete dose escalation portion of Phase 1 clinical trial in 2023; XMT-2056: Initiate Phase 1 clinical trial in the first quarter of 2023. Strategic Objective: Position Mersana as the ADC Partner-of-Choice – Expected Milestones: Pursue impactful new collaborations; Execute against existing collaboration agreements;.